Street analysts have the ability to employ multiple metrics to help calculate target price estimates. The count of Hold ratings in that period was 2. William Blair reaffirmed an ourperform rating on shares of Bristol-Myers Squibb in a research report on Friday, January 20th.
As much as 14 analysts have advised buy on Bristol-Myers Squibb Company (NYSE:BMY) with an average broker rating of 2.07. One analyst has rated the stock with a sell rating, thirteen have given a hold rating and nine have assigned a buy rating to the stock. It is important to note that target price projections can be quite different from analyst to analyst.
Thinly traded micro cap CytomX Therapeutics (NASDAQ:CTMX) jumps 33% premarket on increased volume in response to its announcement that it has expanded its strategic collaboration with Bristol-Myers Squibb (NYSE:BMY), originally inked in 2014, to include eight additional targets using CytomX's Probody platform. The company rocked its 52-Week High of $77.12 on Jul 15, 2016 and touched its 52-Week Low of $46.01 on Jan 26, 2017. Latest closing price was 4.21% above its 50-day moving average and 12.97% above its 200-day moving average.
Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, January 26th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.67 by $0.04.
Bristol-Myers Squibb Company (NYSE:BMY) is expected to post revenue of $4.74 Billion in the current quarter, according to consensus of 12 analysts. Bristol-Myers Squibb's revenue for the quarter was up 22.3% compared to the same quarter past year. During the same period in the previous year, the business posted $0.38 EPS.
Maximum and minimum EPS estimate for the current quarter is projected at $0.8 and $0.66, respectively, according to 14 analysts.
The company also recently announced a quarterly dividend, which will be paid on Monday, May 1st. Perhaps, that suggests something about why 0.34% of the outstanding share supply is held by institutional investors. The ex-dividend date is Wednesday, April 5th. This represents a $1.56 annualized dividend and a dividend yield of 2.77%. Bristol-Myers Squibb's dividend payout ratio is 58.87%. First New York Securities LLC NY bought a new stake in shares of Bristol-Myers Squibb during the third quarter valued at approximately $108,000. It has price to book ratio of 5.83, which gauges the market price of a share over its book value. Also, Director Theodore R. Samuels II acquired 12,000 shares of the company's stock in a transaction that occurred on Monday, February 27th. The stock was purchased at an average cost of $56.77 per share, with a total value of $681,240.00. The disclosure for this sale can be found here. Acropolis Investment Management LLC boosted its position in Bristol-Myers Squibb by 21.3% in the third quarter. Penserra Capital Management LLC now owns 1,959 shares of the biopharmaceutical company's stock valued at $105,000 after buying an additional 956 shares in the last quarter. The firm has floated short ration of 2.84%, hold to candle to sentiment indicator of Short Ratio, which was 3.72.
In the liquidity ratio analysis; quick ratio for most recent quarter was 1.40 while current ratio for time period was 1.60.
The stock showed weekly downbeat performance of -1.17%, which was maintained for the month at 6.70%. State of Alaska Department of Revenue acquired a new position in Bristol-Myers Squibb during the third quarter worth approximately $109,000. Likewise, the positive performance for the quarter was recorded as 0.91% and for the year was -6.22%, while the YTD performance remained at -1.29%. Institutional investors and hedge funds own 69.67% of the company's stock.